Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Camp4 Therapeutics is raising $44,999,960.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Josh Mandel-Brehm played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Camp4 Therapeutics
At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platforms proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.

To learn more about Camp4 Therapeutics, visit http://www.camp4tx.com/

Contact:
Josh Mandel-Brehm, President and Chief Executive Officer
617-651-8867
https://www.linkedin.com/in/josh-mandel-brehm-1155154/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved